Calcium gluconate provides calcium ions to the body. In hyperkalaemia, it temporarily protects against myocardial excitability and reduces the toxic effects of hyperkalaemia. In hypocalcaemia, it replenishes deficient calcium levels to correct the imbalance.
Acute severe hyperkalaemia (plasma-potassium concentration above 6.5 mmol/litre or in the presence of ECG changes)Severe acute hypocalcaemiaHypocalcaemic tetanysevere hypocalcemic tetanymoderate-to-severe hypocalcemiaextreme hyperkalemia (serum K+ >7 mEq/L)Tetany (immediate treatment of severe cases)Dietary supplement (growing children, pregnant, lactating and menopausal women)Osteoporosis (adjuvant role to alendronate/HRT/raloxifene)Empirically used in dermatoses, paresthesias, weakness
- Adult
- For acute severe hyperkalaemia: 10% solution by slow intravenous injection, titrated and adjusted to ECG improvement. For severe acute hypocalcaemia or hypocalcaemic tetany: initial slow intravenous injection of 10% solution, with plasma-calcium and ECG monitoring; may be repeated as required or followed by continuous intravenous infusion to prevent recurrence.
- Pediatric
- Children 1–10 yr: 0.8–1.2 g; Young adult 11–24 yr: 1.2–1.5 g
Common
Sense of warmth (on i.v. injection)ConstipationBloatingExcess gas
Serious
- Arrhythmias (if given too rapidly)
- Myocardial infarction (27% higher incidence in subjects receiving calcium supplements)
BictegravirSevere
Database
Clinical effect not specified
Source: DDInter
CeftriaxoneSevere
Database
Drug interaction classified as: others.
Source: DDInter
Clinical effect not specified
Source: DDInter
Drug interaction classified as: synergy.
Source: DDInter
DolutegravirSevere
Database
Clinical effect not specified
Source: DDInter
7 additional unreviewed or low-confidence interactions hidden because their provenance or source detail is insufficient.